NEOHealthcare · Diagnostics & ResearchThe 12 Wall Street analysts covering NeoGenomics, Inc. hold a median 12-month price target of $19 — +19.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 78 of 100 as at 1 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores NeoGenomics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (91): The shares have been drifting up relative to others.
Volatility (33): The share price moves around a lot.
The rank is the raw material. Whether the rules would actually own NeoGenomics, Inc. — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on NEO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +19.9% from it.
Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 29 July 2026 | Needham | Maintains | Buy | $15 → $19 |
| 24 July 2026 | Benchmark | Maintains | Buy | $11 → $16 |
| 29 Apr 2026 | Benchmark | Upgrade | Buy | — |
| 29 Apr 2026 | Benchmark | Upgrade | Buy | $11 |
| 29 Apr 2026 | Leerink Partners | Upgrade | Outperform | $12 → $25 |
| 29 Apr 2026 | Leerink Partners | Upgrade | Outperform | — |
| 29 Apr 2026 | TD Cowen | Maintains | Buy | $13 → $14 |
| 29 Apr 2026 | TD Cowen | Maintains | Buy | — |
| 24 Feb 2026 | Piper Sandler | Maintains | Overweight | — |
| 17 Feb 2026 | Needham | Maintains | Buy | — |
| 12 Jan 2026 | Needham | Reiterates | Buy | — |
| 12 Sept 2025 | TD Cowen | Maintains | Buy | — |
| 2 Sept 2025 | Stephens & Co. | Maintains | Overweight | — |
| 29 Aug 2025 | Needham | Maintains | Buy | — |
| 4 Aug 2025 | Piper Sandler | Maintains | Overweight | — |
| 30 July 2025 | Morgan Stanley | Maintains | Equal-Weight | — |
| 29 July 2025 | Needham | Maintains | Buy | — |
| 29 July 2025 | William Blair | Downgrade | Market Perform | — |
| 6 May 2025 | Piper Sandler | Maintains | Overweight | — |
| 1 May 2025 | Morgan Stanley | Maintains | Equal-Weight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 96% of US stocks
Cheaper than 45% of US stocks
Cheaper than 39% of US stocks
Cheaper than 2% of US stocks
Higher than 58% of US stocks
Higher than 51% of US stocks
Higher than 58% of US stocks
Higher than 30% of US stocks
Higher than 22% of US stocks
Higher than 38% of US stocks
Higher than 37% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NEO appears on the weeks it earns a place.
NeoGenomics held its Q2 2026 earnings call, and the transcript of that call was published by Seeking Alpha.
Why it matters — Earnings-call transcripts provide investors and analysts with a full, unedited account of management's commentary on the quarter's results and outlook.
NeoGenomics reported second-quarter revenue growth above its prior outlook, driven by higher-value clinical testing and next-generation sequencing expansion, prompting the company to raise its full-year 2026 revenue and adjusted EBITDA guidance.
Why it matters — The raised guidance signals stronger-than-expected business momentum, which is a key indicator for NEO shareholders tracking the company's earnings trajectory.
NeoGenomics announced its second-quarter financial results for the period ended June 30, 2026, via a Business Wire release from its Fort Myers, Florida headquarters.
Why it matters — Quarterly results offer NEO watchers a regular update on the company's financial performance and operational trajectory.
The 12 Wall Street analysts covering NeoGenomics, Inc. have a median 12-month price target of $19, with estimates ranging from $16 to $35. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 12 analysts covering NeoGenomics, Inc., 8 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks NeoGenomics, Inc. 78 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 1 Aug 2026, NeoGenomics, Inc. ranks 78 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (91 of 100).
No one can know that. What the data says: the median 12-month target from 12 analysts implies +19.9% from the last close, and Ticker Nerd's factor model ranks NeoGenomics, Inc. 78 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering NeoGenomics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NEO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $16 to $35 over the next 12 months.
NeoGenomics, Inc. returned +207.0% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
NeoGenomics Inc. is a leading cancer diagnostics company specializing in oncology genetics testing and information services.
The most recent item we track (Seeking Alpha, 29 July 2026): "NeoGenomics, Inc. (NEO) Q2 2026 Earnings Call Transcript". NeoGenomics held its Q2 2026 earnings call, and the transcript of that call was published by Seeking Alpha.
NeoGenomics Inc. is a leading cancer diagnostics company specializing in oncology genetics testing and information services. It offers one of the most comprehensive menus of oncology-focused tests worldwide, including next-generation sequencing (NGS), comprehensive genomic profiling, and advanced assays like RaDaR ST for molecular residual disease (MRD) detection in solid tumors and PanTracer Pro for integrated diagnostics in advanced-stage cancers. The company provides clinical cancer testing, professional interpretation by pathologists and molecular experts, clinical trials support, research services, validation laboratory services, and oncology data solutions to pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, and managed care organizations across the United States and Europe. NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories in multiple U.S. locations and the United Kingdom, with its Pharma Services Division supporting drug development for pharmaceutical clients. Founded in 1998 and headquartered in Fort Myers, Florida, NeoGenomics plays a key role in precision oncology by enabling personalized cancer diagnosis and treatment.
CEO Mr. Anthony P. Zook · 2,500 employees · United States · https://www.neogenomics.com